Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 1-arm
NCT07355257
TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
Safety and Efficacy of Telitacicept in Inflammatory Myopathies
Sponsor: Zhongming Qiu
Conditions
Inflammatory Myopathy
Interventions
Telitacicept 240mg
Updated 1 time since 2026 Last updated: Jan 19, 2026 Started: Feb 2, 2026 Primary completion: Dec 30, 2026 Completion: Mar 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2/PHASE3 clinical study on Inflammatory Myopathy, this trial is actively recruiting participants. The trial is conducted by Zhongming Qiu and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2/PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Zhongming Qiu
Data source: Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.